Systemic lupus erythematosus pathophysiology: Difference between revisions

Jump to navigation Jump to search
Mmir (talk | contribs)
Mmir (talk | contribs)
Line 110: Line 110:
The current paradigm is that LN results from immune complex deposition in the renal glomeruli leading to complement activation, chronic inflammation and renal insufficiency defined by histopathology and the presence of proteinuria and cellular casts.<div style="-webkit-user-select: none;">
The current paradigm is that LN results from immune complex deposition in the renal glomeruli leading to complement activation, chronic inflammation and renal insufficiency defined by histopathology and the presence of proteinuria and cellular casts.<div style="-webkit-user-select: none;">
==Genetics==
==Genetics==
Systemic lupus erythematosus is transmitted in [[polygenic inheritance]] pattern. [[Genes]] involved in the [[pathogenesis]] of systemic lupus erythematosus include [[HLA]] class [[polymorphism]], [[complement system]] related [[genes]], and other genes related to [[Immune systems|immunologic system]] as well.
Systemic lupus erythematosus is transmitted in [[polygenic inheritance]] pattern. [[Genes]] involved in the [[pathogenesis]] of systemic lupus erythematosus include [[HLA]] class 2 especially DR2 nd DR3, HLA class 3 especially complement genes include C2 and C4 genes, IFNRF5 gene, and other genes related to [[Immune systems|immunologic system]] as well.


The following evidence is also suggestive of the [[genetic predisposition]] of SLE:<ref name="pmid10768211">{{cite journal |vauthors=Sullivan KE |title=Genetics of systemic lupus erythematosus. Clinical implications |journal=Rheum. Dis. Clin. North Am. |volume=26 |issue=2 |pages=229–56, v–vi |year=2000 |pmid=10768211 |doi= |url=}}</ref>
The following evidence is also suggestive of the [[genetic predisposition]] of SLE:<ref name="pmid10768211">{{cite journal |vauthors=Sullivan KE |title=Genetics of systemic lupus erythematosus. Clinical implications |journal=Rheum. Dis. Clin. North Am. |volume=26 |issue=2 |pages=229–56, v–vi |year=2000 |pmid=10768211 |doi= |url=}}</ref>

Revision as of 21:50, 27 July 2017

https://https://www.youtube.com/watch?v=0junqD4BLH4&wmode=transparent%7C350}}

Systemic lupus erythematosus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Systemic lupus erythematosus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Lupus and Quality of Life

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Systemic lupus erythematosus pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Systemic lupus erythematosus pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Systemic lupus erythematosus pathophysiology

on Systemic lupus erythematosus pathophysiology

Systemic lupus erythematosus pathophysiology in the news

Blogs onSystemic lupus erythematosus pathophysiology

Directions to Hospitals Treating Systemic lupus erythematosus

Risk calculators and risk factors for Systemic lupus erythematosus pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2] Cafer Zorkun, M.D., Ph.D. [3] Raviteja Guddeti, M.B.B.S. [4]

Overview

The pathophysiology of systemic lupus erythematosus involves the immune system. There are other factors like genetic factors, hormonal abnormalities, and environmental factors that play some roles as well. The most prominent events involving immune abnormalities are related to persistent activation of B cells and plasma cells that make auto-antibodies during disease progression. The most prominent events involving hormonal abnormalities are due to prolactin and estrogen. The most important environmental factors related to disease progression are ultraviolet (UV) light and some infections. On microscopic histopathological analysis, apoptotic keratinocytes, vacuolization of the basement membrane, and dermal mucin deposition are characteristic findings of SLE dermatitis, and active or inactive endocapillary or extracapillary segmental glomerulonephritis are characteristic findings of SLE nephritis.

Pathogenesis

The progression of systemic lupus erythematosus (SLE) involves the immune system. Nearly all of the pathological manifestation of SLE are due to antibody formation and the creation and deposition of immune complexes in different organs of the body. When the immune complexes are formed, they will deposit in different body tissues and vessels, which may lead to complement activation and more organ damage. There are other factors like genetic factors, hormonal abnormalities, and environmental factors that play some roles as well.

Immune abnormalities

Development of systemic lupus erythematosus (SLE) is the due to activation of different mechanisms that may result in auto-immunity. As a result, body tissues lose their self-tolerance. Affected patients are no longer entirely tolerant to all of their self-antigens, consequently progress to an autoimmune disease and develop auto antibodies as a response. During disease progression, B cells and plasma cells that make autoantibodies are more persistently activated and thus make more autoantibodies. These autoantibodies are targeted predominantly to intracellular nucleoprotein particles.[1][2] This increase in autoantibody production and persistence is supposed to be downregulated by anti-idiotypic antibodies or regulatory immune cells, but the massive immunologic response in SLE prevents this downregulation to take place. The most important immune abnormalities that are related to SLE development and progression are: 


Signaling abnormalities

  • Protein kinases are responsible for intracellular cytokine signal. Intracellular signaling is leading to various types of cell response, such as:
    • Cell migration
    • Cell proliferation
    • Inflammatory response
  • Cell signaling abnormalities will lead to:
    • T and B lymphocytes cellular hyperactivity
    • T and B lymphocytes hyper responsiveness
    • Persistence of autoreactive T cells that would otherwise have been deleted
  • Signaling abnormalities of T and B lymphocytes, may be due to:

General

  • Increased expression of specific genetic factors that may be associated with promoting autoimmunity
  • Increased expression of interferon alpha (IFN-α) inducible RNA transcripts by mononuclear cells leads to elevated levels of IFN-α.[3] Increased availability of stimulatory nucleic acids would implicate IFN-I production, that is responsible for chronic and recurrent characteristics of the SLE.
  • Elevated levels of circulating TNF-alpha correlate with active disease, and TNF is expressed in renal tissue in lupus nephritis
  • Abnormally high levels of CD4 on erythrocytes (E-CD4) and low levels of erythrocyte complement receptor type one (E-CR1) are characteristic of SLE, and combined measurement of the 2 molecules has high diagnostic sensitivity and specificity for lupus

Neutrophil

Microparticles

B-Cell related

T-Cell related


Hormonal abnormalities

The following evidence is suggestive of the hormonal predisposition to SLE:

Hormones that are related to disease progression:[7]

Environmental factors


Lupus nephritis

In the initial phase of the disease, the immune deposits and/or autoantibodies induce cytokine production in renal resident cells, leading to further inflammatory cytokine/chemokine expression and leukocyte infiltration and activation. Then, infiltrate leukocytes, such as macrophages (Mφ) and dendritic cells (DCs), secrete a variety of cytokines and activate naïve T cells, leading the cytokine profile towards T helper (Th)1, Th2, and/or Th17.

The current paradigm is that LN results from immune complex deposition in the renal glomeruli leading to complement activation, chronic inflammation and renal insufficiency defined by histopathology and the presence of proteinuria and cellular casts.

Genetics

Systemic lupus erythematosus is transmitted in polygenic inheritance pattern. Genes involved in the pathogenesis of systemic lupus erythematosus include HLA class 2 especially DR2 nd DR3, HLA class 3 especially complement genes include C2 and C4 genes, IFNRF5 gene, and other genes related to immunologic system as well.

The following evidence is also suggestive of the genetic predisposition of SLE:[10]

  • Increase of disease occurrence in identical twins
  • Increased disease frequency among first degree relatives
  • The increased risk of developing the disease in siblings of SLE patients
Classification Gene subtype Function Pathological effect
HLA HLA class2
12867584
  • Contain genes encoding glycoproteins that process and present peptides for recognition by T cells (Antigen presentig cells)
  • The most important related genes:
    • HLA-DR2
    • HLA-DR3
  • Associated with an overall 2 to 3 fold increase in the risk of SLE
  • More in European and Asian
  • HLA-DQ and HLA-DR alleles:
    • Show strong associations with SLE autoantibodies
HLA class3

11079100

  • Contain important immune genes including:
    • C2 gene
    • C4 gene
    • Encode complement proteins
  • The complement system act through opsonization:
    • Facilitates the clearance of apoptotic debris and cellular fragments
    • The fragments might contain nuclear antigens, which are targets for SLE-associated autoantibodies
  • Complement C4-A has a higher affinity for immune complexes
  • Circulating complement C4 proteins clear immune complexes
  • Complete C2 and C4 deficiencies:
    • Rare
    • Associated with a mild form of SLE that affects mostly the joints and skin
  • Stronger genetic evidence for an association with SLE in C4A than C4-B
  • Circulating complement C4 proteins deficiency will promote autoimmunity
Non-HLA Interferon (IFN) regulatory factor 5
20080916
  • Code a transcription factor in the type 1 interferon pathway
  • Regulates:
    • Expression of IFN-dependent genes
    • Inflammatory cytokines
    • Genes involved in apoptosis
  • The most strongly and consistently SLE-associated loci outside the MHC region
  • Upon activation, IRF5 activates transcription of type I IFN and pro-inflammatory cytokines such as TNFα, IL-12 and IL-6
  • Specific combinations of several polymorphisms in the IRF5 region interact to increase disease risk
STAT4 
18579578
19109131
18516230 18803832
  • Encodes the signal transducer and activator of transcription 4 protein
  • associated with a more- severe SLE phenotype:
    • Disease-onset at a young age (<30 years)
    • High frequency of nephritis
  • The presence of antibodies towards double-stranded DNA
  • An increased sensitivity to IFN-α signaling in peripheral blood mononuclear cells
PTPN22
19302045
  • Encodes a lymphoid-specific phosphatase that inhibits T-cell activation
  • Associated with a higher risk of developing multiple autoimmune diseases
  • In European populations
  • Increases the intrinsic lymphoid-specific phosphatase activity that lead to:
    • Reduced T-cell receptor (TCR) signaling threshold
    • Promotes autoimmunity
FcγR genes
10413210
  • Encode proteins that :
    • Recognize immune complexes
    • Involved in antibody-dependent responses
  • Mutation associated with:
    • Low affinity for IgG2-opsonized particles
    • Reduced clearance of ICs
C1q genes

11079100

  • Encode complement proteins:
    • Through opsonization, facilitates the clearance of apoptotic debris and cellular fragments
    • These fragments might contain nuclear antigens, which are targets for SLE-associated autoantibodies.

Homozygous deficiency of C1q:

  • Very rare disease
  • Develop a severe and early onset form of SLE
  • Associated with severe glomerulonephritis and skin manifestations
The IRAK1-MECP2 region
  • Encode a protein kinase:
    • Regulates multiple pathways in both innate and adaptive immune responses by linking several immune-receptor-complexes to TNF receptor-associated factor 6
    • Critical role in the transcriptional suppression of methylation-sensitive genes
TREX1
  • Encodes a major exonuclease:
    • Proofreads DNA polymerase
    • Functions also as a DNA-degrading enzyme in granzyme-A-mediated apoptosis
    • Act as a cytosolic DNA sensor
  • Impairs DNA damage repair lead to the following consequences:
    1. Accumulation of endogenous retroelement-derived DNA
    2. Defective clearance of this DNA induces IFN production
    3. An immune-mediated inflammatory response
    4. Systemic autoimmunity
TNFSF4
  • The genes in this loci produce interaction induces the production of co-stimulatory signals to activate T cells.
  • Inhibits the generation and function of IL-10-producing CD4+type 1 regulatory T cells
  • Induces B-cell activation and differentiation
  • Induces IL-17 production
  • Predispose to SLE:
    • Augmenting the interaction between T cells and antigen-presenting cells
    • Influencing the functional consequences of T-cell activation
IL-10
  • Encodes IL-10
  • An important regulatory cytokine with both immunosuppressive and immunostimulatory properties
  • Increased IL-10 production by B cells and monocytes from patients with SLE is known to correlate with disease activity
Regulators of IFNα TNFAIP3 and TNIP1
  • Key regulators of the NFκB signaling pathway
  • Modulate cell activation, cytokine signaling and apoptosis
  • The exact pathogenetics is not completely known
PHRF1
  • Encodes an elongation factor
  • Related to SLE-associated autoantibodies and elevated IFN-α activity
Regulators of Lymphocytes BLK
19180478
  • encodes a protein kinase:
    • Mediates intra-cellular signaling
    • Influences B cells proliferation and differentiation
    • Influence tolerance of B cells
  • More common in Chinese and Japanese populations
BANK1
  • A B-cell adaptor protein
  • Regulates direct coupling between a family of tyrosine kinases and the calcium channel IP3R
  • Facilitates the release of intracellular calcium
  • Alter the B-cell activation threshold
  • Lead to hyperctivation of B-cell receptors and the subsequent B-cell hyperactivity that is commonly observed in SLE
LYN
  • Mediates B-cell activation
  • Mediates B-cell inhibition
ETS1 
  • Negatively regulates the differentiation of B cells and type 17 T-helper cells
  • Regulates lymphocytes by inhibiting the function of an important transcription factor in plasma cells
IKZF1
  • Lymphoid-restricted transcription factor
  • Regulates:
    • Lymphocyte differentiation and proliferation
    • Self-tolerance through regulation of B-cell-receptor signaling
  • A novel SLE susceptibility locus in a Chinese population
  • A strong candidate locus in European-derived populations
Genes involved in immune complex clearance ITGAM
  • The encoded protein binds the complement cleavage fragment of C3b
  • Contributed to SLE susceptibility

Associated Conditions

Gross Pathology

On gross pathology of kidney, bilateral pallor, and hypertrophy of kidneys are characteristic findings of systemic lupus erythematosus.

On gross pathology of brain, infarct regions and hemorrhages are characteristic findings of systemic lupus erythematosus.

On gross pathology of cardiac valves, cardiomegaly and valvular vegetation are characteristic findings of systemic lupus erythematosus.

On gross pathology of pleura, pleuritis and pleural fibrosis are characteristic findings of systemic lupus erythematosus.

Microscopic Pathology

On microscopic histopathological analysis, apoptotic keratinocytes, vacuolization of the basement membrane, and dermal mucin deposition are characteristic findings of SLE dermatitis, and active or inactive endocapillary or extracapillary segmental glomerulonephritis are characteristic findings of SLE nephritis.

Skin involvement histopathology:

Common shared histopathologic features among all different subtypes of cutaneous lupus include:

SLE dermatitis subtype Specific microscopic findings
Acute cutaneous lupus erythematosus
Subacute cutaneous lupus erythematosus
Chronic cutaneous lupus erythematosus

Glomerulonephritis histopathology:

Class SLE nephritis subtype Light microscopy findings Electron microscopy/Immunofluorescence findings
I Minimal mesangial lupus nephritis -
II Mesangial proliferative lupus nephritis
III Focal lupus nephritis
IV Diffuse lupus nephritis
  • Subendothelial deposits specially during the active phase
  • Diffuse wire loop deposits with little or no glomerular proliferation
V Lupus membranous nephropathy
VI Advanced sclerosing lupus nephritis

Synovial involvement histopathology

Mucosal involvement histopathology


Videos

{{#ev:youtube|Tw07BFaDEo0}}

References

  1. Elkon K (1995). "Autoantibodies in systemic lupus erythematosus". Curr Opin Rheumatol. 7 (5): 384–8. PMID 8519610.
  2. Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O, Komisar O, Slonimsky E, Klang E, Lotan E, Welt M, Marai I, Shina A, Amital H, Shoenfeld Y (2015). "A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients". Autoimmun Rev. 14 (1): 75–9. doi:10.1016/j.autrev.2014.10.003. PMID 25449682.
  3. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, Ly N, Woodward RN, Fry KE, Lau AY, Prentice JG, Wohlgemuth JG, Crow MK (2004). "Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus". Arthritis Rheum. 50 (12): 3958–67. doi:10.1002/art.20798. PMID 15593221.
  4. Barnado A, Crofford LJ, Oates JC (2016). "At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases". J. Leukoc. Biol. 99 (2): 265–78. doi:10.1189/jlb.5BT0615-234R. PMID 26658004.
  5. Dye JR, Ullal AJ, Pisetsky DS (2013). "The role of microparticles in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus". Scand. J. Immunol. 78 (2): 140–8. doi:10.1111/sji.12068. PMID 23672591.
  6. Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW (2007). "Reproductive and menopausal factors and risk of systemic lupus erythematosus in women". Arthritis Rheum. 56 (4): 1251–62. doi:10.1002/art.22510. PMID 17393454.
  7. 7.0 7.1 Lahita RG (1999). "The role of sex hormones in systemic lupus erythematosus". Curr Opin Rheumatol. 11 (5): 352–6. PMID 10503654.
  8. Hughes GC, Choubey D (2014). "Modulation of autoimmune rheumatic diseases by oestrogen and progesterone". Nat Rev Rheumatol. 10 (12): 740–51. doi:10.1038/nrrheum.2014.144. PMID 25155581.
  9. Cohen-Solal JF, Jeganathan V, Grimaldi CM, Peeva E, Diamond B (2006). "Sex hormones and SLE: influencing the fate of autoreactive B cells". Curr. Top. Microbiol. Immunol. 305: 67–88. PMID 16724801.
  10. Sullivan KE (2000). "Genetics of systemic lupus erythematosus. Clinical implications". Rheum. Dis. Clin. North Am. 26 (2): 229–56, v–vi. PMID 10768211.
  11. Petry F, Botto M, Holtappels R, Walport MJ, Loos M (2001). "Reconstitution of the complement function in C1q-deficient (C1qa-/-) mice with wild-type bone marrow cells". J. Immunol. 167 (7): 4033–7. PMID 11564823.
  12. Li R, Peng H, Chen GM, Feng CC, Zhang YJ, Wen PF, Qiu LJ, Leng RX, Pan HF, Ye DQ (2014). "Association of FCGR2A-R/H131 polymorphism with susceptibility to systemic lupus erythematosus among Asian population: a meta-analysis of 20 studies". Arch. Dermatol. Res. 306 (9): 781–91. doi:10.1007/s00403-014-1483-5. PMID 24997134.
  13. Sepehr A, Wenson S, Tahan SR (2010). "Histopathologic manifestations of systemic diseases: the example of cutaneous lupus erythematosus". J. Cutan. Pathol. 37 Suppl 1: 112–24. doi:10.1111/j.1600-0560.2010.01510.x. PMID 20482683.

Template:WH Template:WS